JPS6140206B2 - - Google Patents
Info
- Publication number
- JPS6140206B2 JPS6140206B2 JP53128648A JP12864878A JPS6140206B2 JP S6140206 B2 JPS6140206 B2 JP S6140206B2 JP 53128648 A JP53128648 A JP 53128648A JP 12864878 A JP12864878 A JP 12864878A JP S6140206 B2 JPS6140206 B2 JP S6140206B2
- Authority
- JP
- Japan
- Prior art keywords
- dhpa
- virus
- araa
- adenine
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 8
- 229930024421 Adenine Natural products 0.000 claims description 7
- 229960000643 adenine Drugs 0.000 claims description 7
- -1 dihydroxypropyl Chemical group 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000028 nontoxic concentration Toxicity 0.000 claims 1
- GSLQFBVNOFBPRJ-YFKPBYRVSA-N (2s)-3-(6-aminopurin-9-yl)propane-1,2-diol Chemical compound NC1=NC=NC2=C1N=CN2C[C@H](O)CO GSLQFBVNOFBPRJ-YFKPBYRVSA-N 0.000 description 30
- 241000700605 Viruses Species 0.000 description 16
- 230000000840 anti-viral effect Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 11
- IUUBODMNDCMSEU-UHFFFAOYSA-N 3-[6-amino-3-(3-hydroxypropyl)-2,4,5,9-tetrahydropurin-2-yl]propan-1-ol Chemical compound NC1=NC(CCCO)N(CCCO)C2N=CNC12 IUUBODMNDCMSEU-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 7
- 102000055025 Adenosine deaminases Human genes 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 208000003265 stomatitis Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000005925 vesicular stomatitis Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000450599 DNA viruses Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- GSLQFBVNOFBPRJ-RXMQYKEDSA-N (2r)-3-(6-aminopurin-9-yl)propane-1,2-diol Chemical compound NC1=NC=NC2=C1N=CN2C[C@@H](O)CO GSLQFBVNOFBPRJ-RXMQYKEDSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LNSNHUUHIDLEOY-UHFFFAOYSA-N 3-(6-amino-7h-purin-2-yl)propane-1,2-diol Chemical compound NC1=NC(CC(O)CO)=NC2=C1NC=N2 LNSNHUUHIDLEOY-UHFFFAOYSA-N 0.000 description 1
- DKGIDXRLFYRRKD-UHFFFAOYSA-N 9-[(2-methyl-4-methylidene-5-oxooxolan-2-yl)methyl]-3h-purin-6-one Chemical compound C1=NC(C(N=CN2)=O)=C2N1CC1(C)CC(=C)C(=O)O1 DKGIDXRLFYRRKD-UHFFFAOYSA-N 0.000 description 1
- LVRCEUVOXCJYSV-UHFFFAOYSA-N CN(C)S(=O)=O Chemical compound CN(C)S(=O)=O LVRCEUVOXCJYSV-UHFFFAOYSA-N 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 description 1
- 101150035354 araA gene Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS776839A CS199093B1 (en) | 1977-10-20 | 1977-10-20 | Antiviral agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5480427A JPS5480427A (en) | 1979-06-27 |
| JPS6140206B2 true JPS6140206B2 (US07714131-20100511-C00038.png) | 1986-09-08 |
Family
ID=5416334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12864878A Granted JPS5480427A (en) | 1977-10-20 | 1978-10-20 | Pharmaceutical composition having antiiviral property |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS5480427A (US07714131-20100511-C00038.png) |
| CH (1) | CH642543A5 (US07714131-20100511-C00038.png) |
| CS (2) | CS199093B1 (US07714131-20100511-C00038.png) |
| DE (1) | DE2845762A1 (US07714131-20100511-C00038.png) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6455001U (US07714131-20100511-C00038.png) * | 1987-10-01 | 1989-04-05 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL64501A (en) * | 1980-12-22 | 1985-07-31 | Astra Laekemedel Ab | 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use |
| DE3323621A1 (de) * | 1982-07-08 | 1984-03-01 | Yamasa Shoyu K.K., Choshi, Chiba | Pharmazeutisches praeparat mit die antitumor-wirkung verstaerkender wirkung, ein solches praeparat enthaltende chemotherapeutische zusammensetzung und verwendung des praeparates zur unterstuetzung der antitumor-behandlung beim menschen und tier |
-
1977
- 1977-10-20 CS CS776839A patent/CS199093B1/cs unknown
-
1978
- 1978-09-20 CS CS786066A patent/CS199095B1/cs unknown
- 1978-10-19 CH CH1083178A patent/CH642543A5/de not_active IP Right Cessation
- 1978-10-20 JP JP12864878A patent/JPS5480427A/ja active Granted
- 1978-10-20 DE DE19782845762 patent/DE2845762A1/de active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6455001U (US07714131-20100511-C00038.png) * | 1987-10-01 | 1989-04-05 |
Also Published As
| Publication number | Publication date |
|---|---|
| CS199095B1 (en) | 1980-07-31 |
| DE2845762C2 (US07714131-20100511-C00038.png) | 1987-05-27 |
| CS199093B1 (en) | 1980-07-31 |
| JPS5480427A (en) | 1979-06-27 |
| DE2845762A1 (de) | 1979-04-26 |
| CH642543A5 (en) | 1984-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2813783C (en) | Methods and compositions for inhibition of polymerase | |
| JPH06508846A (ja) | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療 | |
| US4230708A (en) | Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents | |
| JPS6051112A (ja) | 抗ウイルス配合組成物 | |
| US5039667A (en) | Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides | |
| GB2184653A (en) | Dementia improving and therapeutic agents | |
| AU623341B2 (en) | Antiviral therapy for hepatitis b | |
| JPS6259223A (ja) | 医薬組成物 | |
| JPS59186985A (ja) | ジメチルアミノメチレン化された抗ヘルペス化合物 | |
| JPS6140206B2 (US07714131-20100511-C00038.png) | ||
| CA1261265A (en) | METHOD OF MEDICAL TREATMENT OF HUMAN VIRAL DISEASES UTILIZING 1-.beta.-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3- CARBOXAMIDE | |
| JP2003516962A (ja) | 視神経損傷および網膜損傷の処置のためのアデノシンキナーゼのインヒビター | |
| JP2023551467A (ja) | ５’－ｏ－フェニルアセチルウリジン及び治療上の使用 | |
| Diana et al. | Chemotherapy of virus diseases | |
| CN100998639A (zh) | 苦豆子总碱在制备治疗口腔单纯性疱疹和口腔溃疡药物中的应用 | |
| WO2020099696A1 (es) | Uso de ésteres derivados del ácido gálico como antivirales | |
| KR960015953B1 (ko) | 피부에 축적하는 외용의 항바이러스성 약학적 조성물 및 그 제조방법 | |
| US6080746A (en) | Methods and compositions for the prophylaxis and treatment of cytomegalovirus infections | |
| CA1112571A (en) | Therapeutic application of (s)- and (rs)-9-(2,3- dihydroxypropyl) adenine | |
| JPH04178328A (ja) | 血管新生阻害剤 | |
| EP0082667A1 (en) | Pharmaceutical compositions | |
| JPH01501478A (ja) | ９―置換グアニン | |
| EP4199931A1 (en) | Promoiety strategy to enhance drug activity | |
| JPH07179347A (ja) | 抗ウイルス組成物 | |
| Cronin | Antiviral agents |